Imperial College London


Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Professor of Practice (Metabolic Medicine & Endocrinology)



+44 (0)20 3313 8038t.tan




6N6ECommonwealth BuildingHammersmith Campus





Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.



Hinds CE, Owen BM, Hope DCD, et al., 2021, A glucagon analogue decreases body weight in mice via signalling in the liver., Sci Rep, Vol:11

Khoo B, Tan TMM, 2021, Surpassing insulin glargine in type 2 diabetes with tirzepatide, The Lancet, Vol:398, ISSN:0140-6736, Pages:1779-1781

McGlone ER, Manchanda Y, Jones B, et al., 2021, Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling, Molecular Metabolism, Vol:53, ISSN:2212-8778, Pages:1-11


Davies I, Kenkre J, Alexiadou K, et al., 2021, Can current methods of predicting T2D remission following metabolic surgery be improved?, 12th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S13-S13, ISSN:0960-8923

Malallah K, Alexiadou K, Tabbakh Y, et al., 2021, Roux-en-Y gastric bypass and Sleeve Gastrectomy exhibit energy expenditure equally one-year post-surgery, 12th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S8-S9, ISSN:0960-8923

More Publications